

Kinin Receptors & Endothelium-Dependent Responses

Bibliography of One Hundred Key Papers

selected by **Paul M. Vanhoutte, MD, PhD**

IRIS - Courbevoie - FRANCE

-
- Aptecar E, Teiger E, Dupouy P, et al.** *Effects of bradykinin on coronary blood flow and vasomotion in transplant patients.*
J Am Coll Cardiol. 2000;35:1607-1615.
-
- Arcaro G, Zenere BM, Saggiani F, et al.** *ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria.*
Diabetes Care. 1999;22:1536-1542.
-
- Atkinson J, Tatchum-Talom R, Corman B.** *Effect of chronic ANG I-converting enzyme inhibition on aging processes. III. Endothelial function of mesenteric arterial bed of rat.*
Am J Physiol. 1994;267:R136-R143.
-
- Auch-Schwelk W, Duske E, Claus M, Graf K, Gräfe M, Fleck E.** *Endothelium-mediated vasodilation during ACE inhibition.*
Eur Heart J. 1995;16(suppl C):59-65.
-
- Bassenge E.** *Control of coronary blood flow by autacoids.*
Basic Res Cardiol. 1995;90:125-141.
-
- Benacerraf S, Carville C, Adnot S, et al.** *Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.*
J Cardiovasc Pharmacol. 1999;34:368-373.
-
- Bennett MA, Thurston H.** *Effect of angiotensin-converting enzyme inhibitors on resistance artery structure and endothelium-dependent relaxation in two-kidney, one-clip Goldblatt hypertensive and sham-operated rats.*
Clin Sci. 1996;90:21-29.
-
- Berkenboom G.** *Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors.*
Am J Cardiol. 1998;82:11S-13S.
-
- Berkenboom G, Bréchine D, Unger P, Grosfils K, Staroukine M, Fontaine J.** *Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta.*
Hypertension. 1995;26:738-743.
-
- Brunner-La Rocca HP, Vaddadi G, Esler MD.** *Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.*
J Am Coll Cardiol. 1999;33:1163-1173.
-

Bibliography of One Hundred Key Papers

- Bijlstra PJ, Smits P, Lutterman JA, Thien T.** *Effect of long-term angiotensin-converting enzyme inhibition on endothelial function in patients with the insulin-resistance syndrome.* **J Cardiovasc Pharmacol.** 1995;25:658-664.
-
- Busse R, Fleming I, Hecker M.** *Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.* **J Cardiovasc Pharmacol.** 1993;22(suppl 5):S31-S36.
-
- Cargnoni A, Comini L, Bernocchi P, et al.** *Role of bradykinin and eNOS in the anti-ischaemic effect oftrandolapril.* **Br J Pharmacol.** 2001;133:145-153.
-
- Cervenka L, Malý J, Karasová L, et al.** *Angiotensin II-induced hypertension in bradykinin B₂ receptor knockout mice.* **Hypertension.** 2001;37:967-973.
-
- Chen K, Zhang XW, Dunham EW, Zimmerman BG.** *Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension.* **Hypertension.** 1996;27:85-89.
-
- Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC.** *Functional effects of endogenous bradykinin in congestive heart failure.* **J Am Coll Cardiol.** 1998;31:1679-1686.
-
- Chillon JM, Baumbach GL.** *Effects of an angiotensin-converting enzyme inhibitor and a β -blocker on cerebral arteriolar dilatation in hypertensive rats.* **Hypertension.** 2001;37:1388-1393.
-
- Cosentino F, Lüscher TF.** *Maintenance of vascular integrity: role of nitric oxide and other bradykinin mediators.* **Eur Heart J.** 1996;16(suppl K):4-12.
-
- Dendorfer A, Wolfrum S, Dominiak P.** *Pharmacology and cardiovascular implications of the kinin-kallikrein system.* **Jpn J Pharmacol.** 1999;79:403-426.
-
- De Meyer GRY, Herman AG.** *Vascular endothelial dysfunction.* **Prog Cardiovasc Dis.** 1997;39:325-342.
-
- Di Mario C, Ruygrok PN, Serruys PW.** *Vascular remodeling in coronary artery disease.* **J Cardiovasc Pharmacol.** 1997;24(suppl 3):S5-S15.
-
- Drexler H.** *Endothelial dysfunction: clinical implications.* **Prog Cardiovasc Dis.** 1997;39:287-324.
-
- Dusting GJ, Hyland R, Hickey H, Makdissi M.** *Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries.* **Am J Cardiol.** 1995;76:24E-27E.
-
- Ekelund U.** *Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo.* **Acta Physiol Scand.** 1996;118:29-37.
-
- Emanuelli C, Salis MB, Figueroa C, et al.** *Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse.* **Br J Pharmacol.** 2000;30:1076-1082.
-



-
- Erdős EG, Deddish PA, Marcic BM.** *Potentialiation of bradykinin actions by ACE inhibitors.*
Trends Endocrinol Metab. 1999;10:223-229.
-
- Ferrari R, Bachetti T, Guardigli G, Ceconi C.** *Bradykinin and coronary artery disease.*
Eur Heart J. 2000;2(suppl 4):H14-H19.
-
- Ferreira SH.** *Angiotensin converting enzyme: history and relevance.*
Sem Perinatol. 2001;24:7-10.
-
- Figueroa CD, Marchant A, Novoa U, et al.** *Differential distribution of bradykinin B₂ receptors in the rat and human cardiovascular system.*
Hypertension. 2001;37:110-120.
-
- Fogari R, Zoppi A.** *Benefits of the bradykinins beyond blood pressure control: insulin sensitivity and thrombogenesis.*
Eur Heart J. 2000;2(suppl H):H7-H13.
-
- Fogari R, Zoppi A, Lazzari P, et al.** *ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.*
J Cardiovasc Pharmacol. 1998;32:616-620.
-
- Furberg CD, Pitt B.** *Are all angiotensin-converting enzyme inhibitors interchangeable?*
J Am Coll Cardiol. 2001;37:1456-1460.
-
- Gohlke P, Unger T.** *Chronic low-dose treatment with perindopril improves cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin.*
Am J Cardiol. 1995;76:41E-45E.
-
- Goto K, Fujii K, Onaka U, Abe I, Fujishima M.** *Renin-angiotensin system blockade improves endothelial dysfunction in hypertension.*
Hypertension. 2000;36:575-580.
-
- Goto K, Fujii K, Onaka U, Abe I, Fujishima M.** *Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction.*
Hypertension. 2000;36:581-587.
-
- Harrap SB, O'Sullivan JB.** *Cardiac transplantation, perindopril, and left ventricular hypertrophy in spontaneously hypertensive rats.*
Hypertension. 1996;28:622-626.
-
- Hickey H, Makdissi M, Hyland R, Wilks D, Dusting GJ.** *Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits.*
J Mol Cell Cardiol. 1996;28:1985-1994.
-
- Hornig B, Arakawa N, Drexler H.** *Effect of ACE inhibitor on endothelial dysfunction in patients with chronic heart failure.*
Eur Heart J. 1998;19:G48-G53.
-
- Hornig B, Drexler H.** *Endothelial function and bradykinin in humans.*
Drugs. 1995;54(suppl 5): 42-47.
-
- Hornig B, Kohler C, Drexler H.** *Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.*
Circulation. 1997;95:1115-1118.
-

Bibliography of One Hundred Key Papers

- Hu K, Gaudron P, Anders HJ, et al.** *Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT₁-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.* **Cardiovasc Res.** 1998;39:401-412.
-
- Iwatsubo H, Nagano M, Sakai T, et al.** *Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension.* **Hypertension.** 1997;29 (pt 2):286-290.
-
- Jaberansari MT, Baxter GF, Muller CA, et al.** *Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium.* **J Am Coll Cardiol.** 2001;37:1996-2001.
-
- Jeserich M, Pape L, Just H, et al.** *Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure.* **Am J Cardiol.** 1995;76:1079-1082.
-
- Katoh M, Egashira K, Kataoka C, et al.** *Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats.* **Am J Physiol Heart Circ Physiol.** 2001;280:H2306-H2312.
-
- Keaton AK, White CR, Berecek KH.** *Captopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive rat.* **Clin Exp Hypertens.** 1998;20:847-866.
-
- Kichuk MR, Seyedi N, Zhang XP, et al.** *Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation.* **Circulation.** 1996;94:44-51.
-
- Kim S, Zhan Y, Izumi Y, Iwao H.** *Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.* **Hypertension.** 2000;35:769-774.
-
- Kirkwood FA Jr.** *Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease.* **Coron Artery Dis.** 1998;9:675-684.
-
- Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M.** *Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide.* **Hypertens Res.** 2000;23:253-259.
-
- Kuga T, Egashira K, Mohri M, et al.** *Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo.* **Circulation.** 1995;92:183-189.
-
- Linz W, Wiemer G, Schölkens BA.** *Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.* **Diabetes.** 1996;45(suppl 1):551-558.
-
- Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G.** *Interactions among ACE, kinins and NO.* **Cardiovasc Res.** 1999;43:549-561.
-



-
- Madeddu P, Milia AF, Salis MB, et al.** *Renovascular hypertension in bradykinin B₂-receptor knockout mice.* **Hypertension.** 1998;32:503-509.
-
- Madeddu P, Varoni MV, Palomba D, et al.** *Cardiovascular phenotype of a mouse strain with disruption of bradykinin B₂-receptor gene.* **Circulation.** 1997;96:3570-3578.
-
- Mancini GBJ.** *Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.* **Clin Invest Med.** 2000;23:144-161.
-
- Mancini JGB, Henry GC, Macaya C, et al.** *Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.* **Circulation.** 1996;94:258-265.
-
- Marceau F, Hess JF, Bachvarov DR.** *The B₁ receptors for kinins.* **Pharmacol Rev.** 1998;3:358-382.
-
- Marceau F, Larrivée JF, Bouthillier J, Bachvarova M, Houle S, Bachvarov DR.** *Effect of endogenous kinins, prostanoids, and NO on kinin B₁ and B₂ receptor expression in the rabbit.* **Am J Physiol.** 1999;277:R1568-R1578.
-
- Margolius HS.** *Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease.* **Hypertension.** 1995;26:221-229.
-
- Matsumoto K, Morishita R, Moriguchi A, et al.** *Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model.* **Hypertension.** 2001;37:270-274.
-
- McLean PG, Perretti M, Ahluwalia A.** *Kinin B₁ receptors and the cardiovascular system: regulation of expression and function.* **Cardiovasc Res.** 2000;48:194-210.
-
- Mombouli JV.** *ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.* **Drugs.** 1997;54(suppl 5):12-22.
-
- Mulder P, Devaux B, El Fertak L, et al.** *Vascular and myocardial protective effects of converting enzyme inhibition in experimental heart failure.* **Am J Cardiol.** 1995;76:28E-33E.
-
- Naitoh M, Suzuki H, Arakawa K, et al.** *Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension.* **Am J Physiol.** 1997;272:H679-H687.
-
- Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K.** *Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure.* **J Am Coll Cardiol.** 1994;24:1321-1327.
-
- O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R.** *Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.* **J Clin Invest.** 1997;100:678-684.
-

Bibliography of One Hundred Key Papers

- Ono H, Ono Y, Frohlich ED.** *ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.*
Hypertension. 1996;27:176-183.
-
- Pan HL, Chen SR, Scicli GM, Carretero OA.** *Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning.*
Am J Physiol Heart Circ Physiol. 2000;279:H116-H121.
-
- Panzenbeck MJ, Loughnan CL, Madwed JB, Winqvist RJ, Fogal SE.** *Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na⁺-depleted marmosets.*
Am J Physiol. 1995;269:H1221-H1228.
-
- Parratt JR, Vegh A, Papp JG.** *Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning—a brief review of the evidence.*
Can J Physiol Pharmacol. 1995;73:837-842.
-
- Partovian C, Benetos A, Pommiers JP, Mischler W, Safar ME.** *Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin.*
Am J Physiol. 1998;274:H1423-H1428.
-
- Persson K, Whiss PA, Nyhlén K, Jacobsson-Strier M, Glindell M, Andersson RGG.** *Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro.*
Eur J Pharmacol. 2000;406:15-23.
-
- Pesquero JB, Bader M.** *Molecular biology of the kallikrein-kinin system: from structure to function.*
Braz J Med Biol Res. 1998;31:1197-1203.
-
- Prasad A, Narayanan S, Husain S, et al.** *Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition.*
Circulation. 2000;102:35-41.
-
- Regoli D, Barabé J.** *Pharmacology of bradykinin and related kinins.*
Pharmacol Rev. 1980;32:1-46.
-
- Regoli D, Gobeil F, Nguyen QT, et al.** *Bradykinin receptor types and B₂ subtypes.*
Life Sci. 1994;55:735-749. Minireview.
-
- Reid JL, O'Kane K, Squire I.** *Bradykinin—a contribution to blood pressure reduction with ACE inhibition in man?*
Eur Heart J Suppl. 2000;2(suppl H):H3-H6.
-
- Ruocco NA, Bergelson BA, Yu TK, Gavras I, Gavras H.** *Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin.*
Clin Exp Hypertens. 1995;17:1059-1072.
-
- Sharma JN, Amrah SS, Noor AR.** *Suppression of hypotensive responses of captopril and enalapril by the kallikrein inhibitor aprotinin in spontaneously hypertensive rats.*
Pharmacology. 1995;50:363-369.
-
- Sharma JN, Uma K, Noor AR, Rahman ARA.** *Blood pressure regulation by the kallikrein-kinin system.*
Gen Pharmacol. 1996;27:55-63.
-



-
- Schiffrin EL.** *The endothelium of resistance arteries: physiology and role in hypertension.*
Prostaglandins Leukot Essent Fatty Acids. 1996;54:17-25.
-
- Schölkens BA.** *Kinins in the cardiovascular system.*
Immunopharmacology. 1996;33:209-216.
-
- Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE.** *Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease.*
Hypertension. 2000;36:220-225.
-
- Squire IB, O'Kane KPJ, Anderson N, Reid JL.** *Bradykinin B₂ receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men.*
Hypertension. 2000;36:132-136.
-
- Su JB, Barbe F, Crozatier B, Campbell DJ, Hittinger L.** *Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.*
J Cardiovasc Pharmacol. 1999;34:700-710.
-
- Su JB, Hoüel R, Héloire F, et al.** *Stimulation of bradykinin B₁ receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs. Comparison with B₂ receptor stimulation.*
Circulation. 2000;101:1848-1853.
-
- Sudhir K, Chou TM, Hutchinson SJ, Chatterjee K.** *Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo. Differential contribution of nitric oxide and bradykinin in conductance and resistance arteries.*
Circulation. 1996;93:1734-1739.
-
- Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A.** *Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients.*
J Hypertens. 1998;16:447-456.
-
- Thuillez C, Mulder P, Elfertak L, et al.** *Prevention of endothelial dysfunction in small and large arteries in a model of chronic heart failure.*
Am J Hypertens. 1995;8:7S-12S.
-
- Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF.** *Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.*
Circulation. 1994;89:2212-2218.
-
- Unger T, Azizi M, Belz GG.** *Blocking the tissue renin-angiotensin system: the future cornerstone of therapy.*
J Hum Hypertens. 2000;14(suppl 2):S23-S31.
-
- van Ampting JMA, Hijmering ML, Beutler JJ, et al.** *Vascular effects of ACE inhibition independent of the renin-angiotensin system in hypertensive renovascular disease.*
Hypertension. 2001;37:40-45.
-
- Van Belle E, Vallet B, Auffray JL, et al.** *NO synthesis is involved in structural and functional effects of ACE inhibitors in injured arteries.*
Am J Physiol. 1996;270:H298-H305.
-

Bibliography of One Hundred Key Papers

- Varin R, Mulder P, Tamion F, et al.** *Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure. Role of nitric oxide, prostanoids, oxidant stress, and bradykinin.*
Circulation. 2000;102:351-356.
-
- Wiemer G, Schölkens BA, Linz W.** *Endothelial protection by converting enzyme inhibitors.*
Cardiovasc Res. 1994;28:166-172.
-
- Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ.** *Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm.*
Hypertension. 2000;37:1136-1140.
-
- Wojakowski W, Gminski J, Siemianowicz K, Goss M, Machalski M.** *The influence of angiotensin converting enzyme inhibitors on lipid peroxidation in sera and aorta of rabbits in diet-induced hypercholesterolemia.*
Int J Mol Med. 2000;6:591-594.
-
- Yoshiji H, Kuriyama S, Kawata M, et al.** *The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.*
Clin Cancer Res. 2001;7:1073-1078.
-
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, and the Heart Outcomes Prevention Evaluation Study Investigators.** *Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.*
N Engl J Med. 2000;342:145-153.
-
- Zanziger J, Zheng X, Bassenge E.** *Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism.*
Cardiovasc Res. 1994;28:209-214.
-
- Zhang XP, Scicli GA, Xu XB, Nasjletti A, Hintze TH.** *Role of endothelial kinins in control of coronary nitric oxide production.*
Hypertension. 1997;30:1105-1111.
-
- Zhu YC, Stauss HM, Bao G, et al.** *Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors.*
Can J Physiol Pharmacol. 1995;73:827-831.
-
- Zhuo JL, Casley D, Murone C, Mendelsohn FAO.** *Acute and chronic in vivo inhibition of angiotensin-converting enzyme by perindopril in the endothelium and adventitia of large arteries and organs of the rabbit.*
J Cardiovasc Pharmacol. 1997;29:297-310.
-